Repligen Corp (NAS:RGEN)
$ 166.895 -4.885 (-2.84%) Market Cap: 9.33 Bil Enterprise Value: 9.56 Bil PE Ratio: 667.58 PB Ratio: 4.73 GF Score: 93/100

Repligen Corp at UBS Global Healthcare Conference (Virtual) Transcript

May 18, 2020 / 05:20PM GMT
Release Date Price: $135.71 (-3.40%)
Jon K. Snodgres
Repligen Corporation - CFO & Secretary

Hello, everyone.

Sondra S. Newman
Repligen Corporation - Global Head of IR

Hi, Jon. This is Sondra Newman. And I'm filling in for the moment for Dan, who I believe is tied up with a keynote speaker, but we do have some questions for Dan that I'll pass along to Jon. Dan, if you join at any time, feel free to just step in here.

So I think what is on everyone's mind and we're fielding a lot of questions about COVID and the impact on Repligen, the impact on our operations, the ability to keep manufacturing facilities open. And just generally, how this might be shifting demand for our products? So very -- in a very big picture, Jon, could you comment on how things have changed at Repligen with the pandemic?

Jon K. Snodgres;Sondra S. Newman
Repligen Corporation - CFO & Secretary

Yes. Sure, Sondra, shall I open up with the -- with an overview, a little bit of an overview of the company, and we can jump into the questions?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot